Skip to main content

Table 2 Current Pediatric CAR-T Cell Therapy Clinical Trials

From: The future of cancer immunotherapy for brain tumors: a collaborative workshop

Antigen target

Cellular product

Key inclusion

NCT number

GD2

CAR-T

H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG)

NCT04196413

GD2

CAR-T + C7R

high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) or medulloblastoma or another rare brain cancer that expresses GD2

NCT04099797

B7-H3

CAR-T

CNS disease for which there is no standard therapy, or diagnosis of DIPG or DMG at any time point following completion of standard therapy

NCT04185038

IL-13Ra2

CAR-T

Recurrent/Refractory Malignant Brain Tumors

NCT04510051

Her2

CAR-T

recurrent or refractory HER2-positive CNS tumors

NCT03500991

Her2

CAR-T

progressive recurrent or refractory HER2-positive primary central nervous system (CNS) tumor or HER2 positive tumor metastatic to the CNS

NCT02442297

EGFR 806

CAR-T

children and young adults with recurrent or refractory EGFR-positive CNS tumors

NCT03638167